Search results
One of the organization's primary objectives is to establish an internationally recognized set of guidelines on the diagnosis and assessment of renal disease in small animals (IRIS Staging of Chronic Kidney Disease, CKD).
- IRIS Staging of CKD
We recommend that IRIS CKD Stage 1 patients with persistent...
- IRIS Grading of AKI
In the future, the Board intends to expand these guidelines...
- Iris Treatment Recommendations
A persistent increase in SDMA above 14 µg/dl suggests...
- Guidelines
The mission of IRIS is to help veterinary practitioners...
- Related Sites
ACVIM Consensus Statement - Guidelines for the...
- Education
Welcome to the website of the International Renal Interest...
- About IRIS
One of the organization's primary objectives is to establish...
- Hemodialysis Academy
The 2020-2021 Hemodialysis Academy provides more than 160...
- IRIS Staging of CKD
Treatment Guidelines for Chronic Kidney Disease in Dogs and Cats. Understanding the diagnostic and therapeutic priorities based on the stage of CKD facilitates appropriate management of dogs and cats with the disease. Here are the International Renal Interest Society Recommendations for treating CKD in dogs and cats.
Diagnosing, Staging, and Treating Chronic Kidney Disease in Dogs and Cats. Chronic kidney disease (CKD) is diagnosed based on evaluation of all available clinical and diagnostic information in a stable patient. Following diagnosis of CKD, the IRIS Board recommends using serum creatinine or SDMA (ideally both) to stage CKD with substaging based ...
We recommend that IRIS CKD Stage 1 patients with persistent proteinuria (UPC ≥ 0.5 for dogs or 0.4 for cats) are not only monitored and thoroughly investigated but also receive standard treatment for proteinuria as currently recommended for IRIS CKD Stages 2 to 4.
1 cze 2024 · All dogs and cats that have sustained an AKI transition through a period of acute kidney disease (AKD) between days 7–90 post-AKI (Bar-Nathan et al., 2022, Chawla et al., 2017), the pathophysiological response of the kidney to an insult or injury.
Chronic kidney disease (CKD) is diagnosed based on evaluation of all available clinical and diagnostic information in a stable patient. The IRIS Board continues to recommend using creatinine, a widely available and well understood test, to diagnose and stage CKD. Symmetric dimethylarginine (SDMA), a new marker of kidney function, may be a useful
Staging of CKD based on blood creatinine concentration. Staging is undertaken following diagnosis of chronic kidney disease (CKD) in order to facilitate appropriate treatment and monitoring of the patient. Staging is based initially on fasting blood creatinine concentration, assessed on at least two occasions in the stable patient.
